Disruption of the Circadian Timing Systems

Mendlewicz, Julien
September 2009
CNS Drugs;2009 Supplement 2, p15
Academic Journal
Depression is one of the leading causes of morbidity worldwide and represents a huge burden to society. As with many other psychiatric disorders, a genetic basis for depression has been identified. Evidence for the role of circadian genes in depression is particularly compelling. Circadian gene mutations are also associated with circadian rhythm disorders such as familial advanced sleep phase syndrome, delayed sleep phase syndrome, and non-24-hour sleep-wake syndrome. Such disorders, plus the other manifestations of a disrupted circadian system such as hormone dysregulation, are often observed among those with depression. This suggests a shared aetiology between circadian disruption and depression, although the exact mechanisms underlying the association are unclear. This paper reviews the molecular mechanisms involved in depression, with an emphasis on circadian genes. Twin studies in depression have reported probandwise concordance rates of 40% and 70% using narrow and broad diagnostic criteria, respectively, and heritability of over 85% for bipolar disorder. In association studies, increased susceptibility to depression has been noted in those with polymorphisms in the following: D-amino-acid-oxidase activator/G30 gene complex, glucocorticoid receptor gene, serotonin transporter gene, tryptophan hydroxylase 2 gene, dopamine transporter gene and G protein-coupled receptor 50 gene. Polymorphisms in these genes have also been linked to a better or worse response to antidepressant therapy, an increased likelihood of responding poorly to adversity and increased suicide ideation. Polymorphisms in the CLOCK, BMAL1, Per3 and TIMELESS genes have been associated with susceptibility to mood disorder, and single nucleotide polymorphisms and haplotypes in several circadian genes have been observed among those displaying certain circadian phenotypes, including worse mood in the evening, insomnia in mania and early, middle or late insomnia in depression. Manipulation of the circadian timing system via sleep deprivation, bright light or pharmacological therapy has also been shown to alleviate depressive symptoms, providing further evidence for the role of circadian dysfunction in depression pathophysiology. The new antidepressant agomelatine is the first melatonergic antidepressant with an innovative mode of action: it is a melatonergic MT1, MT2 receptor agonist and 5-HT2c antagonist, and is able to restore the internal clock, which is profoundly disturbed in depression, thus being efficacious in major depressive disorders. In conclusion, a wealth of evidence is now available supporting a genetic basis for depression. The apparent importance of mutations in the circadian genes in determining disease susceptibility, disease recurrence and response to treatment suggests that the circadian pathway represents an attractive target for pharmacological manipulation to improve management of this debilitating disorder.


Related Articles

  • Clock genes, chronotypes and diseases. Voinescu, Bogdan I. // Human & Veterinary Medicine;Dec2009, Vol. 1 Issue 2, p19 

    Many common diseases in humans (such as cancer, heart disease, diabetes mellitus or psychiatric disorders, such as depression) seem to be linked to disruptions of circadian cycles and to clock genes variation. It is unlikely that such diseases to be caused by a genetic variation within a single...

  • Circadian polymorphisms associated with affective disorders. Kripke, Daniel F.; Nievergelt, Caroline M.; Joo, E. J.; Shekhtman, Tatyana; Kelsoe, John R. // Journal of Circadian Rhythms;2009, Vol. 7, p1 

    Background: Clinical symptoms of affective disorders, their response to light treatment, and sensitivity to other circadian interventions indicate that the circadian system has a role in mood disorders. Possibly the mechanisms involve circadian seasonal and photoperiodic mechanisms. Since...

  • Association Study of a Monoamine Oxiclase A Gene Promoter Polymorphism with Major Depressive Disorder and Antidepressant Response. W-Y Yu, Younger; Shih-Jen Tsai; Chen-Jee Hong; Tai-Jui Chen; Ming-Chao Chen; Chih-Wei Yang // Neuropsychopharmacology;Sep2005, Vol. 30 Issue 9, p1719 

    Monoamine oxidase A (MAOA), a mitochondrial enzyme involved in the degradation of biogenic amines, may be implicated in the pathogenesis of major depressive disorder (MDD) and be related to the therapeutic effects of antidepressants. To elucidate a genetic predisposition of MDD, we studied a...

  • Therapeutic Potential of 5-HT7 Receptors in Mood Disorders. Mnie-Filali, Ouissame; Lambas-Se�as, Laura; Scarna, H�l�ne; Haddjeri, Nasser // Current Drug Targets;Nov2009, Vol. 10 Issue 11, p1109 

    Serotonin (5-HT) exerts its diverse physiological and pharmacological effects through the activation of multiple receptor subtypes. One of the newest members of this family is the 5-HT7 receptor. Increasing investigations on this receptor are currently undertaken to highlight its physiological...

  • Agomelatin Depresyon Tedavisine Ne Getiriyor? Güncel Bir Gözden Geçirme. Cem Cerit; İrem Yaluğ; Esma Akpınar; Anıl Talas; Ali Evren Tufan; Eylem Özten // Yeni Symposium;2013, Vol. 51 Issue 3, p123 

    In this article literature related to the promises of agomelatine, an antidepressant with melatonergic MT-1 and MT- 2 receptor agonism and seratoninergic 5-HT2c receptor antagonism in the context of depression treatment is reviewed. Although the results of studies on the efficacy of agomelatine...

  • Melatonin Treatment of Winter Depression Following Total Sleep Deprivation: Waking EEG and Mood Correlates. Danilenko, Konstantin V; Putilov, Arcady A // Neuropsychopharmacology;Jul2005, Vol. 30 Issue 7, p1345 

    Patients with winter depression (seasonal affective disorder (SAD)) commonly complain of sleepiness. Sleepiness can be objectively measured by spectral analysis of the waking electroencephalogram (EEG) in the 1-10 Hz band. The waking EEG was measured every 3 h in 16 female SAD patients and 13...

  • The rs1801260 CLOCK polymorphism, links to depression, insomnia and diurnal preference -- preliminary findings from a Romanian sample. Voinescu, Bogdan; Thome, Johannes; Orăsan, Remus // Human & Veterinary Medicine;Dec2009, Vol. 1 Issue 2, p67 

    Objective: We investigated the possible effect of the T3111C CLOCK gene polymorphism on depressive disorder, insomnia and diurnal preference. Material and methods: twenty seven subjects, aged 23-71, self-selected from a larger sample of healthy controls and clinically depressed patients were...

  • SLEEP AND CIRCADIAN DYSREGULATION IN DEPRESSIVE ILLNESS. PHARMACOLOGICAL IMPLICATIONS. Cardinali, Daniel P.; Pandi-Perumal, Seithikurippu R.; Brown, Gregory M. // Clinical Neuropsychiatry;Dec2011, Vol. 8 Issue 6, p321 

    Circadian rhythm abnormalities, as shown by sleep/wake cycle disturbances, constitute one the most prevalent signs of depressive illness, advances or delays in the circadian phase, or changes in rhythms' amplitude, being documented in patients with major depressive disorder (MDD), seasonal...

  • The BDNF Val66Met Polymorphism Interacts with Maternal Parenting Influencing Adolescent Depressive Symptoms: Evidence of Differential Susceptibility Model. Zhang, Leilei; Li, Zhi; Chen, Jie; Li, Xinying; Zhang, Jianxin; Belsky, Jay // Journal of Youth & Adolescence;Mar2016, Vol. 45 Issue 3, p471 

    Although depressive symptoms are common during adolescence, little research has examined gene-environment interaction on youth depression. This study chose the brain-derived neurotrophic factor ( BDNF) gene, tested the interaction between a functional polymorphism resulting amino acid...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics